5700nok
0,0 %
Date:2024-07-24Time:17:30:00Latest report:Q1-2024List:Oslo BorsTicker:GENT
Market Cap:879 mnokEnterprise Value:802 mnokNet Sales:142,2 mnokEarnings:-5,54 mnokEmployees:0ISIN:NO0010748866

Ratios

10-year key figure history for Gentian Diagnostics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Gentian Diagnostics with index and moving average MA50 and MA200.

Stockprice:57,00
MA50:47,43
MA200:41,79
Price/MA200:36,4 %
RSI (14):70,9
Price/MA50:20,2 %

Description

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.

Medical Equipment